PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice.

doi:10.3390/ijms27041820

Article

PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice.

International journal of molecular sciences - 13 Feb 2026

Luong David T, Niu Chenchen, Kim Eunice, Tanji Nolan, Duong Ivy, Galero Brandon, Zhang Yong-Jie, Bennett Craig L, La Spada Albert R

Abstract excerpt

Peroxisome-proliferator-activated receptor delta (PPARδ) regulates metabolic, mitochondrial, and inflammatory pathways implicated in neurodegeneration, making it an attractive therapeutic target for amyotrophic lateral sclerosis (ALS). In this study, we evaluated two PPARδ agonists, KD3010 and T3D-959, in two established ALS/FTD mouse models: an AAV-mediated C9orf72 G4C2-repeat expansion model (C9-149R) and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice.

Abstract excerpt

Topics

Related research